DCP1B

Across TCGA pan-cancer cohorts, DCP1B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DCP1B data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher DCP1B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DCP1B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, CESC, and STAD are the cancer types where DCP1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.211	0.706	<.001	15	view →
CESC	OS	Median	II,III,IV	0.047	0.830	<.001	12	view →
STAD	OS	Median	All	0.119	0.539	.042	3	view →
BLCA	DFS	Median	IV	0.077	0.476	<.001	3	view →
UCEC	DFS	Median	All	0.921	0.621	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DCP1B–ESCA (OS)

Open the ESCA breakdown →